Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine
Links shared publicly online about this topic.
- 0total visits
Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine
Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection.
View full resource at news-medical.net
Tags: Vaccination, Flu, Bird Flu, Pharma, Vaccine, News
Most Recently Shared on January 9, 2012 at 8:58 am By:
Bird Flu News: Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine: Co... http://t.co/kN79p053
Advertisement
